Levetiracetam: Part II, the Clinical Profile of a Novel Anticonvulsant Drug

Authors

  • Tim De Smedt,

    1. Laboratory for Clinical and Experimental Neurophysiology - Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium
    Search for more papers by this author
  • Robrecht Raedt,

    1. Laboratory for Clinical and Experimental Neurophysiology - Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium
    Search for more papers by this author
  • Kristl Vonck,

    1. Laboratory for Clinical and Experimental Neurophysiology - Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium
    Search for more papers by this author
  • Paul Boon

    1. Laboratory for Clinical and Experimental Neurophysiology - Reference Center for Refractory Epilepsy, University Hospital Ghent, Ghent, Belgium
    Search for more papers by this author

Address correspondence and reprint requests to: Tim De Smedt, Neurology Department, University Hospital Ghent, Block B, 2nd floor. De Pintelaan 185, 9000 Ghent, Belgium. Tel.: + 32-9-240-33-55, Fax: +32-9-240-33-60; E-mail: T.DeSmedt@UGent.be

ABSTRACT

The objective of this article was to review and summarize the available reports on the profile of the novel anticonvulsant drug levetiracetam (LEV) in a clinical setting. Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article is devoted to the clinical pharmacology and clinical trials of LEV investigating its efficacy and safety as add-on therapy or monotherapy for various seizure types. Finally, results from postmarketing surveillance of LEV are briefly discussed. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties, a favorable long-term retention rate, and a high responder rate, indicating that LEV is an efficient therapeutic option for the treatment of several types of epilepsy.

Ancillary